Congenital Anomalies 2005; **45**, 146–153

ORIGINAL ARTICLE

Elevated susceptibility of newborn as compared with young rats to 2-*tert*-butylphenol and 2,4-di-*tert*-butylphenol toxicity

Mutsuko Hirata-Koizumi[1], Masao Hamamura[2], Hiromi Furukawa[2], Naemi Fukuda[3], Yoshihiko Ito[3], Yumi Wako[4], Kotaro Yamashita[4], Mika Takahashi[1], Eiichi Kamata[1], Makoto Ema[1], and Ryuichi Hasegawa[1]

[1]National Institute of Health Sciences, Setagaya-ku, Tokyo; [2]Panapharm Laboratories, Uto-shi, Kumamoto; [3]Research Institute for Animal Science in Biochemistry and Toxicology, Sagamihara-shi, Kanagawa; and [4]Kashima Laboratory, Mitsubishi Chemical Safety Institute Ltd, Ibaraki, Japan

ABSTRACT **In order to determine the susceptibility of newborn rats to 2-*tert*-butylphenol (2TBP) and 2,4-di-*tert*-butylphenol (DTBP) toxicity, studies were conducted with oral administration from postnatal days (PND) 4 to 21 and the findings were compared with results for young rats exposed from 5 or 6 weeks of age for 28 days. In the newborn rats, specific effects on physical and sexual development and reflex ontogeny were not observed. While there were no clear differences in toxicological profiles between newborn and young rats, the no-observed-adverse-effect levels (NOAELs) differed markedly. For 2TBP, clinical signs such as ataxic gait, decrease in locomotor activity and effects on liver, such as increase in organ weight, were observed and the NOAELs were concluded to be 20 and 100 mg/kg/day in newborn and young rats, respectively. Based on hepatic and renal toxicity (histopathological changes and increase in organ weight with blood biochemical changes), the respective NOAELs for DTBP were concluded to be 5 and 20 mg/kg/day. Therefore, the susceptibility of newborn rats to 2TBP and DTBP was found to be 4–5 times higher than that of young rats.**

Key Words: 2, 4-di-*tert*-butylphenol, 2-*tert*-butylphenol, susceptibility of newborn rats

INTRODUCTION

Protection of humans against disease and injury caused by chemicals in the environment is the ultimate goal of risk assessment and risk management (Landrigan *et al.* 2004). However, the focus has long been solely on adult exposure and toxicity and the fetus via maternal transfer, with little consideration given to early childhood. In the past decade, stimulated especially by the 1993 US National Research Council (NRC) report *Pesticides in the Diets of Infants and Children* (NAS 1993), recognition that special consideration is required for children in risk assessment has grown. The NRC report noted that 'children are not little adults', because of their unique patterns of exposures to environmental hazards and their particular vulnerability.

For the susceptibility of children to environmental chemicals, the early postnatal period (the suckling period) is of particular note. During this period, the infant could be exposed to various chemicals not only through mothers' milk, but also directly, by having chemical-contaminated baby food, mouthing toys or household materials, and so on; however, current risk assessment gives no consideration to toxic effects resulting from direct exposure to chemicals. An approach that adequately takes into account the susceptibility of infancy is urgently required. However, because there is no standard testing protocol intended for direct exposure of preweaning animals (newborn animals) to chemicals, and toxicity studies using newborn animals are complicated by practical difficulties regarding grouping, direct dosing, and general and functional observation, there is only limited information on susceptibility of the newborn at the present.

We therefore have established a new protocol for repeated dose toxicity studies using newborn rats (newborn rat studies) (Koizumi *et al.* 2001) for systematic application. Results have been compared with those of 28-day repeated dose toxicity studies using young rats (young rat studies) to provide a basis of analyzing susceptibility. Since young rat studies are routinely conducted as one of a battery of minimum toxicity tests and data are stored for many chemicals, comparative analyzes should provide important information for considering effects of direct exposure to chemicals during the suckling period.

We have already reported analytical results for eight chemicals (4-nitrophenol, 2,4-dinitrophenol, 3-aminophenol, 3-methylphenol, 1,3-dibromopropane, 1,1,2,2-tetrabromoethane, 2,4,6-trinitrophenol, and tetrabromobisphenol A) (Koizumi *et al.* 2001, 2002, 2003; Fukuda *et al.* 2004; Takahashi *et al.* 2004; Hirata-Koizumi *et al.* 2005). The susceptibility of newborn rats to the toxicity of the first four agents was four times higher than that of their young counterparts at a maximum. For 1,3-dibromopropane and 1,1,2,2-tetrabromoethane, while the doses causing clear toxicity were lower in newborn rats, doses at which toxic signs began to appear were paradoxically higher in the newborn case. These six chemicals had no impact on development in the newborn period and showed similar toxicity profiles in both age groups. For the other two chemicals, there were marked differences in toxicity profile between the newborn and young rats. Especially, in the case of tetrabromobisphenol A, a specific rather than enhanced renal toxicity was observed in newborn case.

In the present investigation, two *tert*-butylphenols, 2-*tert*-butylphenol (2TBP), and 2,4-di-*tert*-butylphenol (DTBP), were chosen for comparative toxicity analysis. 2TBP has been used in the production of agricultural chemicals, aroma chemicals, and resins (New Chemical Index 2001), and DTBP in the production of antioxidants and ultraviolet absorbers (Chemical Products' Handbook 2004). For either chemical, there is no available toxicity information on human. Regarding toxicity to experimental animals, results from young rat studies of both chemicals are available in

Correspondence: Mutsuko Hirata-Koizumi, BSc, Division of Medicinal Safety Science, National Institute of Health Sciences. 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Email: mkoizumi@nihs.go.jp

Received June 17, 2005; revised and accepted September 2, 2005.

Toxicity Testing Reports of Environmental Chemicals of the Japanese government (MHLW 2001a, 2001b), but no other data have been reported regarding repeated dose toxicity. Since the young rats were only evaluated for toxicity profiles and no-observed-effect levels, we re-evaluated the results for a more practical evaluation index, the no-observed-adverse-effect level (NOAEL), which could serve as the basis for determining tolerable daily intake (TDI) or acceptable daily intake (ADI) for risk assessment, and conducted comparative analyzes with newborn rats.

MATERIALS

2-*tert*-Butylphenol (2TBP, CAS no. 88-18-6, purity: 99.97%) and 2,4-di-*tert*-butylphenol (DTBP, CAS no. 96-76-4, purity: 99.67%), obtained from Dainippon Ink and Chemicals, Incorporated (Tokyo, Japan), were dissolved in olive oil and corn oil, respectively. The test solutions were prepared once a week as stability for eight days had been confirmed. All other reagents used in this study were specific purity grade.

METHODS

All studies were performed under Good Laboratory Practice conditions and in accordance with 'Guidance for Animal Care and Use' of Panapharm Laboratories Co., Ltd, Research Institute for Animal Science in Biochemistry and Toxicology, or Mitsubishi Chemical Safety Institute Ltd.

Animals

In the newborn rat studies of 2TBP and DTBP, pregnant SPF Sprague-Dawley rats [Crj:CD(SD)IGS] were purchased at gestation days 13–15 from Charles River Japan Inc. (Yokohama, Japan), and allowed to deliver spontaneously. All newborn were separated from dams at postnatal day (PND) 3 (the date of birth was defined as PND 0), and pooled according to sex. At the same time, 12 foster mothers were selected among dams, based on the nursing condition. Each foster mother suckled four male and four female newborn, assigned to each of the four dose groups, including the controls, up to weaning on PND 21 (termination of dosing). After weaning, the animals of the recovery-maintenance group (see Study Design) were individually maintained for nine weeks.

In the young rat studies, 4–5 week-old males and females of the same strain were obtained from the same supplier as for the newborn rat studies, and used at ages of 5–6 weeks after acclimation.

All animals were maintained in an environmentally controlled room at 20–26°C with a relative humidity of 40–70%, a ventilation rate of more than ten times per hour, and a 12:12 h light/dark cycle. They were allowed free access to a basal diet (MF: Oriental Yeast Co. Ltd, Tokyo, Japan, or LABO MR Stock: Nihon Nosan Kogyo Inc., Yokohama, Japan) and water (sterile tap water or well water treated with sodium hypochlorite) throughout.

Study design

1. 18-day repeated dose toxicity study in newborn rats (newborn rat study)

Newborn rats (12/sex/dose) were administered the test substances by gastric intubation on PNDs 4–21. On PND 22, six males and six females in each treated group were sacrificed for autopsy (the scheduled-sacrifice group). The remaining animals in all groups (6 rats/sex/dose) were maintained for nine weeks without chemical treatment and then sacrificed at 12 weeks of age (the recovery-maintenance group).

Based on the results of dose-finding studies conducted prior to the main study, the dose, which would show clear toxicity, was selected as the top dose, that without potentially toxic effects as the lowest dose, and the medium dose was set between them. In the dose-finding study for 2TBP (oral administration from PNDs 4–21), some clinical signs and suppressed body weight gain were observed at 200 mg/kg and an increase in relative liver weight at 60 mg/kg and more. For DBTP (oral administration from PNDs 4–17), all of the four males and four females died at 500 mg/kg, and the death of one of the four males, an increase in serum total cholesterol and phospholipid, and increase in relative liver weight were noted in the 100 mg/kg group. Therefore, the doses were set at 0, 20, 60, or 200 mg/kg/day for 2TBP and at 0, 5, 40, or 300 mg/kg/day for DTBP.

During the study, the rats' general condition was observed at least once a day (details of clinical signs noted in this study are described in 'Glossary of terms for toxicity testing' [NIHS 1994]). Body weight and food consumption (only the recovery-maintenance period) was examined once or more a week. As developmental parameters, fur appearance, incisor eruption, pinna detachment and eye opening were assessed for physical development, and testes descent or preputial separation and vaginal opening for sexual development (OECD 2004). In addition, reflex ontogeny, such as visual placing reflex, and surface and mid-air righting reflexes, were also examined (Adams 1986; Jensh & Brent 1988). Urinalysis (color, occult blood, pH, protein, glucose, ketone bodies, bilirubin, urobilinogen, sediment, specific gravity, and volume of the urine) was conducted in the last week of the recovery-maintenance period.

At PNDs 22 and 85, blood was collected from the abdominal aorta under ether anesthesia (for 2TBP) or from the postcaval vein under pentobarbital sodium anesthesia (for DTBP) after overnight starvation for the scheduled-sacrifice and recovery-maintenance groups, respectively. One portion was treated with EDTA-2K and examined for hematological parameters, such as the red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell count, platelet count, reticulocyte count and differential leukocyte count. In the recovery-maintenance group, part of the blood was treated with 3.8% sodium citrate, and blood clotting parameters such as prothrombin time (PT) and activated partial thromboplastin time (APTT) were examined. Serum from the remaining portions of blood for both the scheduled-sacrifice and recovery-maintenance groups were analyzed for blood biochemistry (total protein, albumin, albumin-globulin ratio [A/G ratio], glucose, total cholesterol, triglycerides, phospholipid, total bilirubin, urea nitrogen [BUN], creatinine, glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, alkaline phosphatase, γ-glutamyl transpeptidase [γ-GTP], calcium, inorganic phosphorus, sodium, potassium, and chlorine). Following collection of blood, all animals were sacrificed by exsanguination, and all organs and tissues were macroscopically examined. Then, the brain, pituitary gland, thymus, thyroids, heart, lungs, liver, spleen, kidneys, adrenals, testes, epididymides, and ovaries were removed and weighed. Histopathological examination was conducted for the control and the highest dose groups. The above-listed organs were fixed in 10% buffered formalin-phosphate (following Bouin's fixation for testes and epididymides), and paraffin sections were routinely prepared and stained with Hematoxylin-Eosin for microscopy. For other groups, organs with macroscopically abnormal findings or in which chemical-related effects were evident on microscopic examination for the highest dose group, were similarly investigated.

2. 28-day repeated dose toxicity study in young rats (young rat study)

Five to six week old rats were given the test substances by gastric intubation daily for 28 days and sacrificed following the last treatment (the scheduled-sacrifice group). Recovery groups were maintained for two weeks without chemical treatment and sacrificed at 11 or 12 weeks of age. The number of animals was six for each sex/dose for both scheduled-sacrificed and recovery cases.

The doses were selected in the same way as the newborn rat studies. In the 12-day dose-finding study for 2TBP, ataxic gait was observed at 300 mg/kg and more, and increase in relative liver and kidney weight at 500 mg/kg. For DTBP, with 14-day administration, the death of one of the four females, various changes in some blood biochemical parameters, increase in relative liver weights and light gray macules on kidneys were found at 500 mg/kg. Increase in serum phospholipid and relative liver weights were also demonstrated in the 100 mg/kg group. Based on the results, the doses were determined at 0, 4, 20, 100, or 500 mg/kg/day for 2TBP and at 0, 5, 20, 75, or 300 mg/kg/day for DTBP. Recovery groups were set at 0, 100, 500 mg/kg/day for 2TBP and 0, 300 mg/kg/day for DTBP.

During the study, rats were examined for general condition, body weight, food consumption, urinalysis, hematology and blood biochemistry, necropsy findings, organ weights, and histopathological findings in compliance with the Test Guideline in the Japanese Chemical Control Act (Official Name: Law Concerning the Examination and Regulation of Manufacture, etc. of Chemical Substances).

Statistical analysis

Data for body weights, food consumption, urinalysis findings (except for the results of qualitative analysis), hematological, blood biochemical findings (except for differential leukocyte count), and organ weights were analyzed by the Bartlett's test (Bartlett 1937) for homogeneity of distribution. When homogeneity was recognized, Dunnett's test (Dunnett 1964) was conducted for comparison between control and individual treatment groups ($P < 0.01$ or 0.05). If not homogeneous or for qualitative urinalysis data and differential leukocyte count, the data were analyzed using Steel's multiple comparison tests (Steel 1959), or tests of the Dunnett type (Hollander & Wolfe 1973) ($P < 0.01$ or 0.05). For reflex ontogeny, and physical and sexual development parameters in the newborn rat studies, the χ^2-test (Fisher 1922) was conducted ($P < 0.01$ or 0.05).

RESULTS

2-*tert*-butylphenol (2TBP)

Newborn rat study

Various clinical signs such as decrease in locomotor activity, ataxic gait, deep respiration, and muscle weakness were observed throughout the dosing period in the 200 mg/kg group, as shown in Table 1. With 60 mg/kg, transient decrease in locomotor activity was noted on the first dosing day limited to only one of 12 males. Body weights were lowered by 8–17% from dosing day 7 through to the end of the dosing period in males and to recovery-maintenance day 14 in females given 200 mg/kg. At the scheduled sacrifice, there were no hematological changes at any dose, but blood biochemical examination of the 200 mg/kg group showed increases in γ-GTP in both sexes and total protein in males. In addition, significant increase in relative liver weights was noted in 9% of the females in the 60 mg/kg group and in 21–23% of both males and females in the 200 mg/kg group. On histopathological examination, slight hypertrophy of centrilobular hepatocytes was found in one female of the 60 mg/kg group, and in four males and three females from the 200 mg/kg group. During the recovery-maintenance period, no clinical signs were observed and the lowered body weights showed a tendency for recovery. In parameters for physical and sexual development and reflex ontogeny, no definitive changes were detected. At the end of the recovery-maintenance period, no chemical-related changes, also in urinalysis data, were found in any dose group.

The results of the newborn rat study of 2TBP are summarized in Table 2. Since clinical signs and histopathological changes in the liver were observed in the 60 mg/kg group, the NOAEL was concluded to be 20 mg/kg/day.

Young rat study

Ataxic gait were observed sporadically during the dosing period in nine males and 12 females, and decrease in locomotor activity in two females from the 500 mg/kg group. During the dosing period, there were no changes in body weight, food consumption, and urinalysis data. At the scheduled sacrifice, hematological and blood biochemical examination also showed no changes. Eighteen to 19% increases were found in relative liver weights of both sexes receiving 500 mg/kg, but no histopathological changes in liver were observed at any dose. No chemical-related changes were noted during and at the end of the recovery period.

Table 1 Clinical signs observed during the dosing period in the newborn rat study of 2-*tert*-butylphenol

	Dose (mg/kg/day)			
	0	20	60	200
No. animals (Male/Female)	12/12	12/12	12/12	12/12
No. animals with clinical signs				
Decrease in locomotor activity	0/0	0/0	1†/0	12/12
Ataxic gait	0/0	0/0	0/0	4/6
Deep respiration	0/0	0/0	0/0	12/12
Tremors	0/0	0/0	0/0	2/4
Muscle weakness	0/0	0/0	0/0	12/12
Emaciation	0/0	0/0	0/0	2/2
Pale skin	0/0	0/0	0/0	4/2

†Observed only on the first dosing day.

Table 2 Summary of the results of the newborn and young rat study of 2-*tert*-butylphenol

Newborn rat study				
Dose (mg/kg/day)	20	60	200	
Clinical signs	–	M: Decrease in locomotor activity	Various†	
Body weight changes	–	–	8–17%↓	
Blood biochemical changes	–	–	GTP↑, M: TP↑	
Changes in relative organ weights	–	F: Liver 9%↑	Liver 21–23%↑	
Histopathological findings in liver				
– Slight centrilobular hypertrophy of hepatocytes	–	M: 0/6, F: 1/6	M: 4/6, F: 3/6	
Young rat study				
Dose (mg/kg/day)	4	20	100	500
Clinical signs	–	–	–	Ataxic gait F: Decrease in locomotor activity
Body weight changes	–	–	–	–
Blood biochemical changes	–	–	–	–
Changes in relative organ weights	–	–	–	Liver 18–19%↑
Histopathological findings	n.d.	n.d.	n.d.	–

Statistically significant increases ($P < 0.05$) in body weights, blood biochemical parameters and relative organ weights are shown as ↑, while decreases are shown as ↓. Data on histopathological findings are given as no. of animals with the findings/no. of animals examined, according to sex. Changes observed only in males or females are shown as 'M' or 'F', respectively, while neither 'M' nor 'F' is mentioned in the case of changes noted in both sexes. No chemical-related changes were observed in developmental parameters (conducted only in newborn rat study), urinalysis (only in young rat study), and hematological parameters. †Decrease in locomotor activity, ataxic gait, deep respiration, tremors, muscle weakness, emaciation, and pale skin were observed, as shown in Table 1. GTP, γ-GTP; TP, total protein; –, no change; n.d., not determined.

A summary of the results of the young rat study of 2TBP is given in Table 2. The NOAEL was concluded to be 100 mg/kg/day, at which no changes were observed.

2,4-di-*tert*-butylphenol (DTBP)

Newborn rat study

Two males and one female of the 300 mg/kg group were found dead on dosing days 3, 4, and 7. In this group, decrease in locomotor activity (12 males and 12 females), bradypnea (10 males and 10 females), and hypothermia (one male) were observed from the first dosing day, but then the incidence decreased, with disappearance after dosing day 7. Body weights of the 300 mg/kg group were lowered by 15–25% in males and by 9–20% in females during the dosing period, compared with the control values. There were no definitive changes in parameters for physical development and reflex ontogeny in any dose group. At the scheduled sacrifice, blood biochemical examination showed an increase in total bilirubin and a decrease in the A/G ratio in both sexes, an increase in γ-GTP in males, and an increase in total protein and BUN in females of the 300 mg/kg group. In the 300 mg/kg group, there was a 39–51% increase in relative liver weights, a 37–41% increase in relative kidney weights in both sexes, and a 24% decrease in relative spleen weights in males. In the 40 mg/kg group, 14% increases in relative weight of liver were found in females. On histopathological examination, various changes were observed in livers and kidneys in the 300 mg/kg group, as shown in Table 3. Furthermore, periportal fatty degeneration of hepatocytes was evident in one female given 40 mg/kg, and basophilic tubules in kidneys in one animal of each sex receiving 40 mg/kg and one control group male. Regarding parameters of sexual development, a slight delay in preputial separation was noted in the 300 mg/kg group (the incidences were 0/5, compared with 2/6 in the control group at PND 42 [recovery-maintenance day 21]; 0/5, 3/6 at PND 43; 2/5, 5/6 at PND 44; 2/5, 6/6 at PND 46; 4/5, 6/6 at PND 47; and 5/5, 6/6 at PND 48). During this observation period, body weights were lowered by approximately 10% in males given 300 mg/kg than control levels, which was not statistically significant. In the last week of the recovery-maintenance period, there were no chemical-related changes on urinalysis in any dose group. At the end of the recovery period, changes noted in the scheduled-sacrifice group were not observed except for histopathological changes in the kidneys, significant in the 300 mg/kg group (Table 3).

A summary of the results of the newborn rat study of DTBP is shown in Table 4. Since fatty degeneration of hepatocytes and increase in liver weight were demonstrated at 40 mg/kg, the NOAEL was concluded to be 5 mg/kg/day.

Young rat study

No chemical-related changes were found in general condition, body weight, and food consumption at any dose. On urinalysis at the fourth week of dosing, an increase in urine volume, and a decrease in specific gravity and osmotic pressure were noted in both sexes of the 300 mg/kg group. At the scheduled sacrifice, hematological examination showed a decrease in hemoglobin and hematocrit, an increase in segmented neutrophils in females, and prolongation of PT and APTT in males at 300 mg/kg. On blood biochemical examination, there was an increase in total bilirubin in males given 300 mg/kg, and an increase in total cholesterol and phospholipid in females given 75 mg/kg and above. For organ weights, there were

Table 3 Histopathological findings for the newborn rat study of 2,4-di-*tert*-butylphenol

		Scheduled-sacrifice group				Recovery-maintenance group†	
Dose (mg/kg/day)	Grade	0	5	40	300	0	300
No. of animals examined (Male/Female)		6/6	6/6	6/6	5/6	6/6	5/5
Liver							
– Fatty degeneration of periportal hepatocytes	+	0/0	0/0	0/1	0/0	0/0	0/0
	++	0/0	0/0	0/0	3/4	0/0	0/0
	+++	0/0	0/0	0/0	2/2	0/0	0/0
Kidneys							
– Basophilic tubules	+	1/0	n.d.	1/1	4/4	0/0	3/0
– Granular casts	+	0/0	n.d.	0/0	4/2	0/0	0/0
– Cystic dilatation of collecting tubules	+	0/0	n.d.	0/0	0/0	0/0	5/4
	++	0/0	n.d.	0/0	3/4	0/0	0/0
	+++	0/0	n.d.	0/0	2/2	0/0	0/0
– Cellular infiltration of neutrophils	+	0/0	n.d.	0/0	2/1	0/0	1/0
	++	0/0	n.d.	0/0	1/1	0/0	1/0
	+++	0/0	n.d.	0/0	1/1	0/0	0/0

†No histopathological examination was conducted at 5 and 40 mg/kg in the recovery-maintenance group. +, mild; ++, moderate; +++, marked; n.d., not determined.

increases in relative liver weights by 40–43% in both sexes given 300 mg/kg, and by 13% in females receiving 75 mg/kg. On histopathological examination, mild to marked changes in livers and kidneys were observed in both sexes from the 300 mg/kg group, as shown in Table 5. At the end of the recovery period, the increase in total cholesterol and phospholipid and renal histopathological changes observed in the scheduled-sacrifice group remained significant in the highest-dose group (Table 5).

The results of the young rat study are summarized in Table 4. Based on increase in the relative liver weights with some changes in blood biochemical parameters in females given 75 mg/kg, the NOAEL was concluded to be 20 mg/kg/day.

DISCUSSION

During development, many rapid and complex biological changes occur, which can have profound consequences on sensitivity to the effects of exogenous chemicals (Scheuplein *et al.* 2002). Although the neonatal body at birth is reasonably well prepared for the abrupt changes associated with parturition, and most functional systems possess a significant portion of their adult capacity (Dourson *et al.* 2002), it is known that the various functions remain immature in early postnatal period and that some organs and tissues, especially in the nervous, immune and reproductive systems, continue to develop after birth (NAS 1993). Therefore, it is important to evaluate toxic effects by exposure to chemicals during the early postnatal period as well as the fetal period for comprehensive risk assessment. However, economic issues and lack of human resources, arising from practical difficulties regarding protocols, have hindered routine implementation of toxicity studies using newborn animals. Our series of comparative analyzes on susceptibility of the newborn are therefore of particular importance for risk assessment.

In the present study on 2TBP and DTBP, there were no clear differences in toxicity profiles between the newborn and young rats in either case. For 2TBP, clinical signs such as a decrease in locomotor activity and ataxic gait, and effects on liver such as an increase in organ weight were observed. In the DTBP case, hepatic and renal toxicity (histopathological changes, increase in organ weight, etc.) were noted. As a characteristic effect of DTBP on male sexual development, slight delay in preputial separation was also observed in the newborn rat study. Preputial separation, an androgen-dependent process which is an early marker of puberty, represents a reliable non-invasive indicator of chemical-induced perturbation of male pubertal development in the rat (Gaytan *et al.* 1988). However, it is known that decreased body weights can result in non-specific delay in puberty (Ashby & Lefevre 2000). Since DTBP lowered body weights in the period of observation of preputial separation and there were no DTBP-related changes in weights or histopathology of the testes and epididymides, well known to be essentially androgen-dependent, no specific effect on male sexual development could be concluded in the present study. As for NOAELs of both chemicals, clear differences were observed between newborn and young rats, with values of 20 and 5 mg/kg/day in newborn rats, and 100 and 20 mg/kg/day in young rats for 2TBP and DTBP, respectively. Therefore, the susceptibility was four- to five-fold higher in newborn than in young rats.

Our previous analysis of 1,3-dibromopropane and 1,1,2,2-tetrabromoethane (Hirata-Koizumi *et al.* 2005) showed dose–response curves to be very different between newborn and young rats. The same was recently reported for the widely used organophosphorus insecticide, chlorpyrifos (Zheng *et al.* 2000), as well as pyrethroid insecticides (Shafer *et al.* 2005). These data showed the importance of estimating unequivocally toxic levels (UETLs), defined for our comparative toxicity analysis as equivalent toxic doses inducing clear toxicity, including death, clinical toxic signs,

Table 4 Summary of the results of the newborn and young rat study of 2,4-di-*tert*-butylphenol

Newborn rat study				
Dose (mg/kg/day)	5	40	300	
Death	–	–	M: 2/12, F: 1/12	
Clinical signs	–	–	Decrease in locomotor activity bradypnea, hypothermia	
Body weight changes	–	–	9–25%↓	
Urinalysis	n.d.	n.d.	n.d.	
Hematological changes	–	–	–	
Blood biochemical changes	–	–	Various†	
Changes in relative organ weights	–	F: Liver 14%↑	Liver 39–51%↑, Kidney 37–41%↑ M: Spleen 24%↓	
Histopathological findings	–	F: Fatty degeneration in liver	Various changes in liver and kidney‡	
Developmental parameters	–	–	Slight delay in preputial separation	
Young rat study				
Dose (mg/kg/day)	5	20	75	300
Death	–	–	–	–
Clinical signs	–	–	–	–
Body weight changes	–	–	–	–
Urinalysis	–	–	–	UV↑ SG↓ OP↓
Hematological changes	–	–	–	Various§
Blood biochemical changes	–	–	F: Tcho↑ Pho↑	M: TB↑ F: Tcho↑ Pho↑
Changes in relative organ weights	–	–	F: Liver 13%↑	Liver 40–43%↑
Histopathological findings	n.d.	n.d.	–	Various changes in liver and kidney¶

Data on death are shown as no. of dead animals/no. of animals examined, according to sex. Statistically significant increases ($P < 0.05$) in body weights, urinalysis and blood biochemical parameters, and relative organ weights are shown as ↑, while decreases are shown as ↓. Changes observed only in males or females are shown as 'M' or 'F', respectively, while neither 'M' nor 'F' is mentioned in the case of changes noted in both sexes. †Increase in total bilirubin and decrease in the A/G ratio in both sexes, increase in γ-GTP in males, and increase in total protein and BUN in females were noted. ‡Various changes were observed as shown in Table 3. §Various hematological changes were noted such as decrease in hemoglobin and hematocrit and increase in segmented neutrophils in females and prolongation of PT and APTT in males. ¶Various changes were observed as shown in Table 5. OP: osmotic pressure; Pho: phospholipid; SG: specific gravity; TB: total bilirubin; Tcho: total cholesterol; UV: urine volume; –: no change; n.d.: not determined.

or critical histopathological damage (Koizumi *et al.* 2001). We here tried to apply this UETL approach to the present study. For 2TBP, clinical signs such as decrease in locomotor activity and ataxic gait were noted in most of the animals given 200 mg/kg (newborn rats) and 500 mg/kg (young rats) (Table 2). Furthermore, a 8–17% lowering of body weight was observed at 200 mg/kg in newborn rats, but not in the young rat study. Therefore, equivalent toxic effects to these observed at 500 mg/kg in young rats might be expected to appear at 100–150 mg/kg in newborn animals. The UETLs were concluded to be 100–150 and 500 mg/kg/day in newborn and young rats, respectively. In the case of DTBP, clear toxicity was observed at the top dose of 300 mg/kg in both newborn and young rat studies (Table 4), but the level of severity was very different, for example, deaths were only noted in the newborn cases. It was considered difficult to estimate the UETLs from the results of main studies only. However, the most critical endpoint for toxicity, mortality, was also noted at 100 mg/kg and more, and 500 mg/kg, in the dose-finding studies of newborn and young rats, respectively. Therefore, it would be possible to estimate the appropriate UETLs as the minimum lethal dose by taking the results of the dose-finding studies into consideration. The UETLs were concluded to be 100 mg/kg/day for the newborn, and 500 mg/kg/day for young rats, at which one out of eight rats was found dead in both cases. These analyzes of UETLs, considering equivalence in toxic degree, showed 3.3–5.0 times higher susceptibility of newborn rats to 2TBP and DTBP than young rats, consistent with our analytical results for NOAELs.

Higher susceptibility of newborn rats was also demonstrated in our previous analyzes of five phenols (4-nitrophenol, 2,4-dinitrophenol, 3-aminophenol, 3-methylphenol and 2,4,6-trinitrophenol) (Koizumi *et al.* 2001, 2002, 2003; Takahashi *et al.* 2004), considered mainly due to their poor metabolic and excretory capacity (Horster 1977; Cresteil *et al.* 1986). It has actually been reported that UDP-glucuronyltransferase and sulfotransferase activities, when 4-nitrophenol is used as the substrate, are lower in microsomes prepared from livers of newborn rats, and that the elimination rate of 2,4-dinitrophenol from serum of newborn rabbits is markedly slower than in young adults (Gehring & Buerge 1969; Matsui & Watanabe 1982). Unfortunately, there is no information on the toxicity mechanism and toxicokinetics of both 2TBP

Table 5 Histopathological findings for the young rat study of 2,4-di-*tert*-butylphenol

		Scheduled-sacrifice group†			Recovery group	
Dose (mg/kg/day)	Grade	0	75	300	0	300
No. of animals examined (Male/Female)		6/6	6/6	6/6	6/6	6/6
Liver						
– Centrilobular hypertrophy of hepatocytes	+	0/0	0/0	4/4	0/0	0/0
Kidneys						
– Basophilic tubules	+	0/0	0/0	1/4	0/0	3/1
	++	0/0	0/0	4/0	0/0	2/0
	+++	0/0	0/0	1/1	0/0	1/0
– Granular casts	+	0/0	0/0	5/2	0/0	4/0
	++	0/0	0/0	1/1	0/0	0/0
– Proteinaceous casts	+	0/0	0/0	5/1	0/0	2/0
	++	0/0	0/0	1/0	0/0	0/0

†No histopathological examination was conducted for the 5 and 20 mg/kg scheduled-sacrifice groups. +, mild; ++, moderate; +++, marked.

and DTBP; however, the immature functions involved in the toxicokinetics in newborn rats would be implicated in the higher susceptibility, as in the case of five phenols previously analyzed. While there are very little data on toxicokinetics of environmental chemicals in the newborn, relatively plentiful information has been reported in humans for pharmaceuticals which are clinically applied during the early postnatal period. Recently, Ginsberg *et al.* (2002) conducted comparative analysis of pharmacokinetic parameters for 45 drugs in both children and adults, and showed half-lives in children aged two months or under to generally be two-fold longer than in adults.

As for the susceptibility of the newborn to toxicity of chemicals, although it is generally important to take the sensitivity of target organs and tissues themselves (toxicodynamics) into consideration besides toxicokinetics, there are insufficient data on differences between newborn and young/adult animals. For appearance of toxicity, which is the outcome of toxicokinetics and toxicodynamics, some comparative studies have relied on LD_{50} values (Goldenthal 1971; Sheehan & Gaylor 1990). However, it is not considered that information on acute toxicity at lethal dosage is appropriate when considering the susceptibility of newborn in risk assessment, because dose–response curves could differ, as mentioned above. With prolonged, subtoxic doses, which are basis for TDI or ADI, our series of comparative studies constitute the first systematic assessment, providing an important base for development of new methods of risk assessment of susceptibility of the newborn.

In conclusion, clinical signs and effects on the liver were observed for 2TBP, and hepatic and renal toxicity for DTBP. Although there were no clear differences in toxicity profiles between the newborn and young rats for both chemicals, the toxicity levels differed markedly. The susceptibility of the newborn to these chemicals appears to be 4–5 times higher than that of young animals.

ACKNOWLEDGMENT

The authors gratefully acknowledge the financial support of the Office of Chemical Safety, Pharmaceutical and Medical Safety Bureau, Ministry of Health, Labor and Welfare, Japan.

REFERENCES

Adams J (1986) Methods in behavioral teratology. In: Riley EP, Vorhees CV (eds). *Handbook of Behavioral Teratology*. Plenum Press, New York, pp. 67–97.

Ashby J, Lefevre PA (2000) The peripubertal male rat assay as an alternative to the Hershberger castrated male rat assay for the detection of anti-androgens, oestrogens and metabolic modulators. *J Appl Toxicol* **20**: 35–47.

Bartlett MS (1937) Properties of sufficiency and statistical tests. *Proc R Soc Lond Ser A* **160**: 268–282.

Chemical Products' Handbook (2004) *14504 No Kagakushohin*. [Chemical Products of 14504]. The Chemical Daily Co., Ltd, Tokyo. (In Japanese).

Cresteil T, Beaune P, Celier C, Leroux JP, Guengerich FP (1986) Cytochrome P-450 isoenzyme content and monooxygenase activities in rat liver: Effect of ontogenesis and pretreatment by phenobarbital and 3-methylcholanthrene. *J Pharmacol Exp Ther* **236**: 269–276.

Dourson M, Charnley G, Scheuplein R (2002) Differential sensitivity of children and adults to chemical toxicity. II. Risk and regulation. *Regul Toxicol Pharmacol* **35**: 448–467.

Dunnett CW (1964) New tables for multiple comparisons with a control. *Biometrics* **20**: 482–491.

Fisher RA (1922) On the interpretation of chi-square from contingency tables and the calculation of P. *J R Stat Soc* **85**: 87–94.

Fukuda N, Ito Y, Yamaguchi M *et al.* (2004) Unexpected nephrotoxicity induced by tetrabromobisphenol A in newborn rats. *Toxicol Lett* **150**: 145–155.

Gaytan F, Bellido C, Aguilar R, Aguilar E (1988) Balanopreputial separation as an external sign of puberty in the rat: Correlation with histologic testicular data. *Andrologia* **20**: 450–453.

Gehring PJ, Buerge JF (1969) The distribution of 2,4-dinitrophenol relative to its cataractogenic activity in ducklings and rabbits. *Toxicol Appl Pharmacol* **15**: 574–592.

Ginsberg G, Hattis D, Sonawane B *et al.* (2002) Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. *Toxicol Sci* **66**: 185–200.

Goldenthal EI (1971) A compilation of LD50 values in newborn and adult animals. *Toxicol Appl Pharmacol* **18**: 185–207.

Hirata-Koizumi M, Kusuoka O, Nishimura N *et al.* (2005) Susceptibility of newborn rats to hepatotoxicity of 1,3-dibromopropane and 1,1,2,2-tetrabromomethane, compared with young rats. *J Toxicol Sci* **30**: 29–42.

Hollander M, Wolfe DA (1973) *Nonparametric Statistical Methods*. John Wiley and Sons, New York.

Horster M (1977) Nephron function and perinatal homeostasis. *Ann Rech Vet* **8**: 468–482.

Jensh RP, Brent RL (1988) The effects of prenatal X irradiation on the appearance of reflexes and physiologic markers in the neonatal rat. *Radiat Res* **116**: 416–426.

Koizumi M, Nishimura N, Enami T *et al.* (2002) Comparative toxicity study of 3-aminophenol in newborn and young rats. *J Toxicol Sci* **27**: 411–421.

Koizumi M, Noda A, Ito Y *et al.* (2003) Higher susceptibility of newborn than young rats to 3-methylphenol. *J Toxicol Sci* **28**: 59–70.

Koizumi M, Yamamoto Y, Ito Y *et al.* (2001) Comparative study of toxicity of 4-nitrophenol and 2,4-dinitrophenol in newborn and young rats. *J Toxicol Sci* **26**: 299–311.

Landrigan PJ, Kimmel CA, Correa A, Eskenazi B (2004) Children's health and the environment: Public health issues and challenges for risk assessment. *Environ Health Perspect* **112**: 257–265.

Matsui M, Watanabe HK (1982) Developmental alteration of hepatic UDP-glucuronosyltransferase and sulphotransferase towards androsterone and 4-nitrophenol in Wistar rats. *Biochem J* **204**: 441–447.

MHLW (2001a) 2-tert-Butylphenol (88-18-6). In: Ministry of Health, Labor and Welfare (ed). *Toxicity Testing Reports of Environmental Chemicals*, **Vol. 8**. Chemical Investigation Promoting Council, Tokyo, pp. 208–218.

MHLW (2001b) 2,4-Di-tert-butylphenol (96-76-4). In: Ministry of Health, Labor and Welfare (ed). *Toxicity Testing Reports of Environmental Chemicals*, Vol. 8. Chemical Investigation Promoting Council, Tokyo, pp. 372–386.

NAS (National Academy of Sciences) (1993) *Pesticides in the Diets of Infants and Children*. National Academy Press, Washington, DC.

New Chemical Index (2001) *Shin Kagaku Index*. [New Chemical Index.] The Chemical Daily Co., Ltd, Tokyo. (In Japanese).

NIHS (1994) *Glossary of Terms for Toxicity Testing*. Biological Safety Research Center, National Institute of Health Sciences, Tokyo. (In Japanese).

OECD (2004) Draft guidance document on reproductive toxicity testing and assessment, OECD environment, health and safety publications series on testing and assessment No. 43. November 10, 2004 (1st Version).

Scheuplein R, Charnley G, Dourson M (2002) Differential sensitivity of children and adults to chemical toxicity. I. Biological basis. *Regul Toxicol Pharmacol* **35**: 429–447.

Shafer TJ, Meyer DA, Crofton KM (2005) Developmental neurotoxicity of pyrethroid insecticides: Critical review and future research needs. *Environ Health Perspect* **113**: 123–136.

Sheehan DM, Gaylor DW (1990) Analysis of the adequacy of safety factors. *Teratology* **41**: 590–591.

Steel RD (1959) A multiple comparison rank sum test: Treatment versus control. *Biometrics* **15**: 560–572.

Takahashi M, Ogata H, Izumi H *et al.* (2004) Comparative toxicity study of 2,4,6-trinitrophenol (picric acid) in newborn and young rats. *Cong Anom* **44**: 204–214.

Zheng Q, Olivier K, Won YK, Pope CN (2000) Comparative cholinergic neurotoxicity of oral chlorpyrifos exposures in preweanling and adult rats. *Toxicol Sci* **55**: 124–132.

The Journal of Toxicological Sciences,
Vol.30, No.1, 29-42, 2005

SUSCEPTIBILITY OF NEWBORN RATS TO HEPATOTOXICITY OF 1,3-DIBROMOPROPANE AND 1,1,2,2-TETRABROMOETHANE, COMPARED WITH YOUNG RATS

Mutsuko HIRATA-KOIZUMI[1], Osamu KUSUOKA[2], Nobuo NISHIMURA[2], Hajime WADA[3], Hidehiro OGATA[3], Naemi FUKUDA[4], Yoshihiko ITO[4], Eiichi KAMATA[1], Makoto EMA[1] and Ryuichi HASEGAWA[1]

[1] *National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan*

[2] *Gotemba Laboratory, Bozo Research Center Inc., 1284 Kamado, Gotemba-shi, Shizuoka 412-0039, Japan*

[3] *Panapharm Laboratories Co., Ltd., 1285 Kurisakimachi, Uto-shi, Kumamoto 869-0425, Japan*

[4] *Research Institute for Animal Science in Biochemistry and Toxicology, 3-7-11 Hashimotodai, Sagamihara-shi, Kanagawa 229-1132, Japan*

(Received July 22, 2004; Accepted December 10, 2004)

ABSTRACT — Newborn rat studies were conducted with oral administration of 1,3-dibromopropane (DBP) and 1,1,2,2-tetrabromoethane (TBE) from postnatal Days 4 to 21 to allow comparison of NOAELs and unequivocally toxic levels with those from 28-day young rat studies starting at 5-6 weeks of age. The unequivocally toxic level was estimated by our specified criteria, requiring simultaneous change of organ weights, histopathology, some biochemical parameters and body weights, because in this study only hypertrophy of hepatocytes was observed as a major histopathological change. DBP caused centrilobular hypertrophy of hepatocytes with alteration in biochemical parameters, as well as lowering of body weights, regardless of sex, in both newborn and young rats. NOAELs and unequivocally toxic levels were considered to be 50 and 150 mg/kg/day in newborn rats and 10 and 250 mg/kg/day in young rats, respectively. In the newborn rat study of TBE, some hepatic effects observed at the top dose of 50 mg/kg were not considered adverse because of the lack of histopathological changes. Significant lowering of body weight was noted at 200 mg/kg in the dose-finding study but histopathological data were not available. In the young rat study, there was no definite toxicity at 6 mg/kg and hypertrophic changes in liver and thyroids without body weight change occurred at 200 mg/kg. There were no clear sex differences in both the newborn and young rat studies. NOAELs were considered to be 50 and 6 mg/kg/day in newborn and young rats, respectively, but unequivocally toxic levels for both rats could not be estimated. Abnormalities of external and sexual development and reflex ontogeny in the newborn were not observed with either chemical. Based on these results, it can be concluded that the target organ of DBP and TBE is the liver in both newborn and young rats, and that while the doses at which toxic signs began to appear are higher in newborn rats, those causing clear toxicity may be paradoxically lower in the newborn case.

KEY WORDS: Toxicity in newborn rats, 1,3-Dibromopropane, 1,1,2,2-Tetrabromoethane

INTRODUCTION

The newborn period is a time of biological changes because birth creates a completely new situation for the offspring. For example, prior to birth, maternal and fetal blood are in close equilibration, and most xenobiotics that cross the placenta to the fetus must shift back to the mother again because the ability of the fetus to dispose of them is extremely immature (Scheuplein *et al.*, 2002). After elimination of compounds across the placenta ceases at birth, metabolic and excretory functions rapidly develop. In the liver, parturition triggers the dramatic development of metabolic enzymes (Alcorn and McNamara, 2002). In man,

Correspondence: Mutsuko HIRATA-KOIZUMI

most enzymes have matured to adult activity levels by the first year of life, but cytochrome P450-mediated metabolism, glucuronidation, glutathione conjugation and acetylation are generally deficient in the neonate. Regarding renal clearance, although the adult function is also approached by 1 year of age, the faster development of filtering than absorptive or secretory functions results in a glomerulotubular imbalance. The lack of a balanced detoxication ability during the newborn period would be expected to affect toxicity of chemicals.

For the toxicity evaluation of various kinds of chemicals, repeated dose and reproductive/developmental toxicity studies have been generally conducted. However, the effects of direct exposure to chemicals during the newborn period have not been taken into account. Furthermore, there were no sufficient data on the differences between the newborn and young/adult in the susceptibility to the toxicity of chemicals. Therefore, for the purpose of understanding the sensitivity of the newborn and utilizing it in the toxicity evaluation, we conducted the repeated dose toxicity studies using newborn rats, and analyzed the differences of the sensitivity from that of young rats, which have been recently used to evaluate the chemical toxicity in general. These comparative studies were conducted as a part of an existing chemical testing program of Japan. As the candidate chemicals, phenolic and halogenated compounds were selected among chemicals in this program, considering the potential for endocrine disrupting action in the early development period. Because of no standard experimental protocol, repeated dose toxicity studies in newborn rats were conducted with our newly established protocol (Koizumi *et al.*, 2001), including a detailed examination of early development and a complete toxicity analysis after a sufficient recovery-maintenance period. The results were compared with those of a 28-day repeated dose toxicity study using young rats, which is generally conducted as a screening test in existing chemical testing program in Japan. For more precise comparison, in addition to the no observed adverse effect levels (NOAELs), we estimated unequivocally toxic levels, defined as doses inducing clear toxicity, including clinical toxic signs, death or critical histopathological damage. In order to estimate more appropriate NOAELs and unequivocally toxic levels than those depending on the dosages of main studies, the results of dose-finding studies for each case were incorporated. Earlier, we reported analytical results for five chemicals (4-nitrophenol, 2,4-dinitrophenol, 3-aminophenol, 3-methylphenol, tetrabromobisphenol A) (Koizumi *et al.*, 2001, 2002, 2003; Fukuda *et al.*, 2004). The susceptibility of newborn rats to the toxicity of the first four was 2 to 4 times higher than that of their young counterparts, although these chemicals had no impact on development in the newborn period and showed similar toxicity profiles in both age groups (mainly effects on the central nervous system). In the case of tetrabromobisphenol A, a specific rather than enhanced renal toxicity was observed in newborn rats.

In the present study, two halogenated alkanes, 1,3-dibromopropane (DBP) and 1,1,2,2-tetrabromoethane (TBE), were chosen as the sixth and seventh chemicals for comparative toxicity analysis, because these two chemicals have similar properties such as analogous chemical structures and hepatotoxicity after hepatic metabolism, and the lower susceptibility of the newborn to these chemicals was expected in preliminary analysis, contrary to all outcomes of previous analyses. There has hitherto been no sufficient information on toxicity of DBP, an intermediate in the production of pharmaceutical agents (Chemical Products' Handbook, 2004), except that the intraperitoneal lowest lethal dose is 750 mg/kg in mice (Sax, 1979). Applications of TBE are various as a fire retardant, in oils and fats, in solvents, for ore dressing, and as a reagent for microscopic examination and as a catalyst (Chemical Products' Handbook, 2004). Regarding its toxicity, inhalation exposure to TBE for 180-184 days (7 hr/day, 5 days/week) caused slight edema and congestion in lungs and slight centrilobular fatty degeneration in the livers of mice, rats, guinea pigs and rabbits at an average concentration of 4 ppm (Hollingsworth *et al.*, 1963). Gavage studies for 3 weeks using F344/N male rats have been conducted on many halogenated ethanes to examine renal toxicity, but all rats administered TBE (214 mg/kg/day and more) died or were killed on becoming moribund by dosing Day 11 (NTP, 1996). Cytoplasmic vacuolization of hepatocytes was observed in these rats. We have conducted the newborn rat studies on DBP and TBE and evaluated the results in comparison with published findings in young rats (MHLW, 2003a, 2003b), in the same manner as for the five chemicals already documented (Koizumi *et al.*, 2001, 2002, 2003).

MATERIALS AND METHODS

Materials

1,3-Dibromopropane (DBP, CAS No. 109-64-8, purity: 99.8%) and 1,1,2,2-tetrabromoethane (TBE,

CAS No. 79-27-6, purity: 99.2%) were obtained from TOSOH CORPORATION (Tokyo, Japan), and dissolved in corn oil and olive oil, respectively. Test solutions were prepared at least once a week and kept cool and in the dark until dosing. The stability was confirmed to be at least 7 days under these conditions. All other reagents used in this study were specific purity grade.

Animals

Sprague-Dawley SPF rats [Crj:CD(SD)IGS] were purchased from Charles River Japan Inc. (Kanagawa, Japan) and maintained in an environmentally controlled room at 19-27°C with a relative humidity of 32-75%, a ventilation rate of more than 10 times per hour, and a 12:12 hr light/dark cycle. For 18-day newborn rat studies of DBP and TBE, 20 pregnant rats (gestation Day 14) were purchased for each and allowed to deliver spontaneously. All newborn were separated from dams at postnatal Day 3 (the date of birth was defined as postnatal Day 0), and those with good health without external abnormality were pooled according to sex. Groups of 12 males and 12 females were selected and assigned to each of the 4 dose groups, including the controls, by stratified random sampling based on the body weight. Twelve foster mothers were selected based on health and nursing conditions, and suckled the 4 males and 4 females assigned to each group up to weaning on postnatal Day 21 (termination of dosing). After weaning, the animals of the recovery-maintenance group (see Study design) were individually maintained for 9 weeks. In the 28-day study of young rats, 4 week-old rats were obtained and used at ages of 5-6 weeks after acclimation. All animals were allowed free access to basal diet (CRF-1: Oriental Yeast Co. Ltd., Tokyo, Japan, or LABO MR Stock: Nihon Nosan Kogyo Inc., Yokohama, Japan) and water (tap water or well water treated with sodium hypochlorite).

Study design (Time schedule as reported previously (Koizumi *et al.*, 2001))

1. 18-Day repeated dose study in newborn rats

In a dose-finding study, DBP was administered by gastric intubation to newborn rats (5/sex/dose) from postnatal Days 4 to 21 and TBE from postnatal Days 4 to 20. The dosages were set at 0, 10, 30, 100 or 200 mg/kg/day for DBP and at 0, 12, 50 or 200 mg/kg/day for TBE, based on the results of young rat study, mentioned below. They were examined for general behavior and body weights during the dosing period, and sacrificed at postnatal Day 21 or 22 for assessment of hematology, blood biochemistry, macroscopic findings and organ weights.

In the main study, newborn rats (12/sex/dose) were administered test substances by gastric intubation from postnatal Days 4 to 21. Based on results of the dose-finding study, the dosage was set at 10, 50 or 150 mg/kg/day for DBP and 3, 12 or 50 mg/kg/day for TBE. On postnatal Day 22, 6 males and 6 females in each treated group were sacrificed (the scheduled-sacrifice group) and the rest of animals in all groups (6/sex/dose) were maintained for 9 weeks without chemical treatment and then sacrificed at 12 weeks of age (the recovery-maintenance group). During the study, general behavior, body weight and food consumption (only the recovery-maintenance period) were examined at least once a day. In addition, some developmental parameters were assessed, such as surface righting and visual placing reflex for reflex ontogeny, fur appearance, incisor eruption and eye opening for external development, and preputial separation, vaginal opening and estrous cycle for sexual development. Urinalysis (color, pH, occult blood, protein, glucose, ketone bodies, bilirubin, urobilinogen, sediment, volume of the urine, osmotic pressure) was conducted in the late recovery-maintenance period.

At weaning age of postnatal Day 22 after the last treatment, blood was collected under anesthesia from the abdomen of all animals in the scheduled-sacrifice group. In the recovery-maintenance group, it was conducted at 85 days of age after overnight starvation. One portion of the blood was treated with EDTA-2K and examined for hematological parameters such as the red blood cell count (RBC), hemoglobin (Hb), hematocrit (Ht), mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell count, platelet count, reticulocyte count and differential leukocyte count. In the recovery-maintenance group, blood was also treated with 3.8% sodium citrate and blood clotting parameters such as prothrombin time and activated thromboplastin time were examined. Serum or plasma from the remaining portions of blood were analyzed for blood biochemistry (total protein, albumin, albumin-globulin (A/G) ratio, glucose, total cholesterol, triglycerides, phospholipid, total bilirubin, urea nitrogen, creatinine, glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), alkaline phosphatase, γ-glutamyl transpeptidase (γ-GTP), calcium, inorganic phosphorus, sodium, potassium, chlorine). Following collection of blood, all animals were

sacrificed by exsanguination, and organs and tissues of the entire body were macroscopically observed. The brain, pituitary gland, thymus, thyroids, heart, lungs, liver, spleen, kidneys, adrenals, testes, epididymides, ovaries and uterus were weighed, and fixed in 10% buffered formalin-phosphate (following Bouin's fixation for testes and epididymides). Paraffin sections were routinely prepared and stained with hematoxylin-eosin for microscopic examination. All studies were conducted in compliance with the Good Laboratory Practice Act of the Japanese Government.

2. 28-Day repeated dose study in young rats

In a dose-finding study, DBP and TBE were administered by gastric intubation to five-week old rats (5 or 4/sex/dose) for 14 days. The dosages were determined at 0, 20, 60, 200 or 600 mg/kg/day for DBP, and at 0, 10, 20, 50, 100 or 200 mg/kg/day for TBE, based on the results of the preliminary single-dose study. The general behavior, body weight and food consumption were examined, and the animals were sacrificed the day after the last treatment for assessment of hematology, blood biochemistry, macroscopic findings and organ weights.

Referring to the results of the dose-finding study, doses in a main study were set at 10, 50 and 250 mg/kg/day for DBP and at 6, 20, 60 and 200 mg/kg/day for TBP. In the main study, 5-6 week old rats were given the test substances by gastric intubation daily for 28 days and sacrificed after overnight starvation following the last treatment (scheduled-sacrifice group). Recovery groups (0, 50, 250 mg/kg/day for DBP and 0, 200 mg/kg/day for TBE) were maintained for 2 weeks without chemical treatment and sacrificed at 11 or 12 weeks of age. The number of animals for each sex/dose for both scheduled-sacrifice and recovery cases was 6 for DBP and 5 for TBE. Rats were examined for general behavior, body weight, food consumption, urinalysis, hematology and blood biochemistry, necropsy findings, organ weights and histopathological findings in compliance with the Test Guideline in the Japanese Chemical Control Act (Official Name: Law Concerning the Examination and Regulation of Manufacture, etc. of Chemical Substances) under Good Laboratory Practice conditions.

Statistical analysis

Parametric data such as body weights, food consumption, urinalysis findings (except for the results of qualitative analysis), hematological and blood biochemical findings, and organ weights were analyzed by Bartlett's test (Bartlett, 1937) for homogeneity of distribution. When homogeneity was recognized, Dunnett's test (Dunnett, 1964) was conducted for comparison between control and individual treatment groups ($p < 0.01$ or 0.05). If not homogenous, the data were analyzed using Steel's multiple comparison test (Steel, 1959) or the mean rank test of the Dunnett type (Hollander and Wolfe, 1973) ($p < 0.01$ or 0.05). If the number of groups was two, parametric data were analyzed by the F test (Snedecor and Cochran, 1967). When homogeneity was recognized, the Student's *t*-test (Steel and Torrie, 1980) was conducted and if not, the Aspinn-Welch's *t* test (Snedecor and Cochran, 1967) ($p < 0.01$ or 0.05). For histopathological findings, the Mann-Whitney's U test (Mann and Whitney, 1947) or the Fisher's exact test (Fisher, 1973) were performed ($p < 0.01$ or 0.05). In the newborn study, the chi square test (Fisher, 1922) was conducted for physical and sexual development and reflex ontogeny ($p < 0.01$ or 0.05).

Judgment criteria for NOAEL and the unequivocally toxic level

NOAEL is the greatest dose at which no adverse effects are observed. In the case of hepatotoxicity, increased liver weights or changes in biochemical parameters alone are not considered to be adverse effects. The unequivocally toxic level has been used only for our comparative toxicity analysis as a clear toxic dose. However, it is generally not readily definable because it depends on the type of toxicity. In this study, centrilobular hypertrophy of hepatocytes was observed as a major histopathological change with both chemicals. Appearance of hypertrophic hepatocytes may not be considered to be a sign of clear toxicity because it is not usually accompanied by increase in GOT and GPT, typically found with hepatotoxic agents. Therefore, for the special purposes of this study, the unequivocally toxic level was estimated on the basis of concomitant changes in organ weights, histopathology, biochemical parameters and body weights.

RESULTS

1,3-Dibromopropane (DBP)

1. 18-Day study in newborn rats (including the dose-finding study)

In the dose-finding study at doses of 10, 30, 100 and 200 mg/kg, 2 of 5 males and 2 of 5 females of the highest group died on dosing Days 2 to 3, but no

change in general behavior was observed in the others. In the 200 mg/kg group, body weights were also lower by 15-25% than the control values from dosing Day 4 in males and from dosing Day 8 in females. Blood biochemical examination showed a slight increase in total cholesterol in females given 200 mg/kg. For organ weight, increases in relative liver weights were demonstrated in both sexes at 100 mg/kg and more with absolute liver weights in males at 100 mg/kg. Decrease in absolute and relative testis weights were also observed in males of 200 mg/kg group. At autopsy, there were no gross abnormalities except hepatomegaly in all animals, including the dead rats at 200 mg/kg. Based on these results, 10, 50 and 150 mg/kg were selected as the doses for the main study in newborn rats.

In the main study, no change in general behavior was noted during the dosing period in any dose group. Body weights of both sexes given 150 mg/kg were lowered during the dosing period (Fig.1) and gain was also decreased by approx. 10%. No definitive changes in parameters for external and sexual development and reflex ontogeny were detected in any dose group. At the scheduled sacrifice, blood biochemical examination of the 150 mg/kg group showed increases in γ-GTP in males and total bilirubin in females. There were no dose-related changes in hematological parameters. Significant increase of absolute and relative liver weights was noted in males given 50 mg/kg and in both sexes given 150 mg/kg. The relative liver weights were also increased in females at 10 and 50 mg/kg. Absolute brain weights were lower in both sexes given 150 mg/kg, this being considered due to the lowered body weights. On histopathological examination, hypertrophy of centrilobular hepatocytes was noted in all animals given 150 mg/kg, being mild in 3/6 males and 4/6 females (Table 1). In four of each sex, the endoplasmic reticulum in hypertrophic hepatocytes showed a ground glass appearance. In addition, single cell necrosis was also noted in 3/6 males and 1/6 females at 150 mg/kg. During and at the end of the recovery-maintenance period, the changes observed in scheduled sacrificed group had disappeared.

The results of the dose-finding study and main study of DBP in newborn rats are summarized in Table 2. The NOAEL was concluded to be 50 mg/kg/day because increase in liver weight without biochemical and histopathological changes in this dose of the main study was not considered as an adverse effect. The unequivocally toxic level was concluded to be 150 mg/kg/day, based on increase of liver weight, mild centrilobular hypertrophy of hepatocytes, increase of γ-GTP and total bilirubin, and lowering of body weights at this dose in the main study, taking additional account of the 40% mortality rate at 200 mg/kg in the dose-finding study.



Fig. 1. Body weight curves for the 18-day study of 1,3-dibromopropane in newborn rats.
*: Significantly different from the controls ($p < 0.05$), **: Significantly different from the controls ($p < 0.01$).

2. 28-Day study in young rats (including the dose-finding study)

In the 14-day dose-finding study at doses of 20, 60, 200 and 600 mg/kg, all animals died within 6 days after the first treatment in the highest group. They showed various toxic signs such as decrease in spontaneous movement, oligopnea and adoption of a prone/lateral position. Blood biochemical examination showed increase in total protein in males and in total cholesterol in females at 200 mg/kg. Increase in absolute and relative liver weights was observed in both sexes of the 60 and 200 mg/kg groups and relative liver weights in males of 10 mg/kg. In addition, increase was found in relative kidney weights in males and in absolute and relative kidney and heart weights in females at 200 mg/kg. There were no other dose-related changes evident. Based on the results, 250 mg/kg, at which it was predicted that clear toxic signs would appear, was selected as the top dose for the main study, and by one-fifth division 50 and 10 mg/kg were derived.

In the main study, salivation was observed from dosing Day 12 in 5 to 10 of each sex given 250 mg/kg. In males at this dose, body weights were significantly lowered by approx. 10% from dosing Day 18, in spite of no dose-related change in food consumption. On

Table 1. Histological findings for the liver after 18-day repeat dosing of 1,3-dibromopropane in newborn rats (main study).

	Grade	Dose (mg/kg) 0	10	50	150
Males					
No. of animals examined		6	6	6	6
Liver					
– Single cell necrosis	±	0	0	0	3
– Centrilobular hypertrophy of hepatocytes	±	0	0	0	3
	+	0	0	0	3
					*
Females					
No. of animals examined		6	6	6	6
Liver					
– Single cell necrosis	±	0	0	0	1
– Centrilobular hypertrophy of hepatocytes	±	0	0	0	2
	+	0	0	0	4
					*

±: Slight, +: Mild, *: Significantly different from the control group ($p<0.01$).

Table 2. Summary of the results of the repeated dose studies of 1,3-dibromopropane in newborn rats.

	Dose-finding Study (5 rats/sex/dose)				Main Study (6 rats/sex/dose)		
Dose (mg/kg/day)	10	30	100	200	10	50	150
Toxic Effects							
– Death (No. of dead animals)	0	0	0	2M, 2F	0	0	0
– Body weight	–	–	–	15-25%↓	–	–	10%↓
– Blood biochemical parameters	–	–	–	F: Cho (↑)	–	–	M: GTP↑ F: TB↑
– Relative liver weight	–	–	↑	↑	F: ↑	↑	↑
– Histopathological changes ±	n.d.	n.d.	n.d.	n.d.	0	0	3M, 2F
(No of animals with the findings*) +	n.d.	n.d.	n.d.	n.d.	0	0	3M, 4F

±: Slight change, +: Mild change, M: Males, F: Females, ↑: Increase, ↓: Decrease, (↑): Slight increase, –: No change,
Cho: Total cholesterol, GTP: γ-GTP, TP: Total protein, n.d.: No available data, *Centrilobular hypertrophy of hepatocytes.

hematological examination at the scheduled sacrifice, slight anemic changes with decrease in Hb and Ht, and an increased reticulocyte ratio were observed in females receiving 250 mg/kg. At 250 mg/kg, many blood biochemical parameters, including total protein, albumin, total cholesterol, triglycerides, phospholipids and total bilirubin, were also increased with an upward trend of GOT and GPT. With 50 mg/kg, slight increase in total protein was only observed in males. Significant increases were found in absolute and relative liver weights of both sexes at 250 mg/kg and in relative liver weights of females at 50 mg/kg. There was also increase in relative heart weights and relative kidney weights in both sexes of the 250 mg/kg group. On histopathological examination, slight to mild centrilobular hypertrophy of hepatocytes was observed at 50 mg/kg and more (Table 3). Perilobular vacuolation of hepatocytes tended to decrease with the dose. Most of the above changes became less prevalent or disappeared during the recovery period. However, body weights remain lower throughout this period in males and the relative liver and heart weights continued to be

Table 3. Histological findings in the repeated dose study of 1,3-dibromopropane in young rats (main study).

		Scheduled-sacrifice group (mg/kg)				Recovery group (mg/kg)		
	Grade	0	10	50	250	0	50	250
Males								
No. of animals examined		6	6	6	6	6	6	6
Liver								
– Centrilobular hypertrophy of hepatocytes	±	0	0	4	2	0	–	0
	+	0	0	0	4	0	–	0
				*				
				**				
– Perilobular vacuolation of hepatocytes	±	0	1	2	5	5	–	6
	+	6	5	4	1	1	–	0
				**				
Spleen								
– Extramedullary hematopoiesis	±	5	–	–	5	6	3	0
	+	0	–	–	1	0	3	6
	++	1	–	–	0	0	0	0
							**	
– Deposits of brown pigment	±	6	–	–	6	6	6	1
	+	0	–	–	0	0	0	5
							**	
Females								
No. of animals examined		6	6	6	6	6	6	6
Liver								
– Centrilobular hypertrophy of hepatocytes	±	0	0	3	2	0	–	0
	+	0	0	0	4	0	–	0
				**				
– Perilobular vacuolation of hepatocytes	±	1	1	4	5	4	–	5
	+	5	5	2	1	2	–	1
				*				
Spleen								
– Extramedullary hematopoiesis	±	6	–	–	5	6	6	4
	+	0	–	–	1	0	0	2
– Deposits of brown pigment	±	6	–	–	5	4	5	1
	+	0	–	–	1	2	1	5

±: Slight, +: Mild, ++: Moderate, *: Significantly different from the control group ($p<0.05$),
**: Significantly different from the control group ($p<0.01$).

high in females at 250 mg/kg. At the same time, decreases in RBC, Hb, Ht and increase in the reticulocyte ratio appeared in males given 250 mg/kg with an increased incidence of extramedullary hematopoiesis and deposits of brown pigment in the spleen (Table 3).

Summary of the results of the dose-finding and main study of DBP in young rats are shown in Table 4. The NOAEL was concluded to be 10 mg/kg/day from the main study, as the 20 mg/kg in dose-finding study was not appropriate because of the lack of histopathological examination. The unequivocally toxic level was concluded to be 250 mg/kg/day, at which increase of liver weight, mild centrilobular hypertrophy of hepatocytes, increase of many biochemical parameters with an upward trend of GOT and GPT, slight anemic effects and lowering body weight were observed in the main study.

1,1,2,2-Tetrabromoethane (TBE)

1. 18-Day study in newborn rats (including the dose-finding study)

In the dose-finding study, when newborn rats were given TBE at 12, 50 and 200 mg/kg, hypoactivity and bradypnea were observed during the dosing period in all animals of the high dose group, the body weights being lowered by 10-20% in both sexes at dosing Days 8 to 17. On blood biochemical examination for this group, slight increase in total bilirubin was found in both sexes. In addition, absolute and relative liver weights were increased in females receiving the 50 mg/kg and both sexes of the 200 mg/kg group, and relative liver weights in females of the 12 mg/kg and males of the 50 mg/kg groups. There were also increases in relative kidney weights of females and decreases in absolute spleen weights of both sexes and relative spleen weights of females at 200 mg/kg. No significant changes were observed on hematological and gross examination. Based on these results, it was predicted that some hepatotoxicity would be observed at 50 mg/kg, which was selected as the top dose in the main study, and 3 and 12 mg/kg were derived by approx. one-fourth divisions.

In the main study, no significant changes were noted in general behavior and body weight (Fig.2). There were also no definitive changes in the parameters for external and sexual development and reflex ontogeny at any dose. At scheduled sacrifice, blood biochemical examination in the 50 mg/kg group showed only a slight increase in total protein in males. There were also increases in absolute and relative liver weights in both sexes, relative kidney weights in males and relative heart weights in females of the 50 mg/kg group. After the recovery-maintenance period, no significant changes were observed in blood biochemical findings and in kidney and heart weights, but the relative liver weights still remained high in males at 50 mg/kg. There were no dose-related changes in food consumption, urinalysis, hematology and histopathology throughout the study, including the recovery-maintenance period.

As shown in summary of the results in Table 5, in the 50 mg/kg group, relative liver weights were increased in both dose-finding and main studies, and total protein was slightly increased only in males of the main study. These changes without histopathological alteration were not considered adverse effects. Therefore, the NOAEL was concluded to be 50 mg/kg/day. Unfortunately, no histopathological changes in the

Table 4. Summary of the results of the repeated dose studies of 1,3-dibromopropane in young rats.

	Dose-finding Study (5 rats/sex/dose)				Main Study(6 rats/sex/dose)		
Dose (mg/kg/day)	20	60	200	600	10	50	250
Toxic Effects							
–Death (No. of dead animals)	0	0	0	5M, 5F	0	0	0
–Body weight	–	–	–	n.d.	–	–	M: 10%↓
–Blood biochemical parameters	–	–	M: TP↑ F: Cho↑	n.d.	–	M: TP (↑)	Many↑
–Relative liver weight		M: ↑	↑	n.d.	–	F: ↑	↑
–Histopathological changes ±	n.d.	n.d.	n.d.	n.d.	0	4M, 3F	2M, 2F
(No of animals with the findings*) +	n.d.	n.d.	n.d.	n.d.	0	0	4M, 4F

±: Slight change, +: Mild change, M: Males, F: Females, ↑: Increase, ↓: Decrease, (↑): Slight increase, –: No change, Cho: Total cholesterol, TP: Total protein, Many: Many parameters including Cho, TP, albumin, triglycerides, phospholipids and total bilirubin, n.d.: No available data, * Centrilobular hypertrophy of hepatocytes.

liver were observed at the highest dose of 50 mg/kg in the main study, meaning that the dose setting was not appropriate. Therefore, an unequivocally toxic level could not be estimated. The dose of 200 mg/kg in the dose-finding study was clearly toxic because of effects on the central nervous system (hypoactivity and bradypnea) and lowering of body weight (10-20% reduction), although no histopathological examination was conducted.

2. 28-Day study in young rats (including the dose-finding study)

In the dose-finding study with 14-day exposure at 0, 10, 20, 50, 100 or 200 mg/kg, there were no significant changes in body weight, food consumption and urinalysis at any dose. Hematological examination showed increase in reticulocytes of both sexes at 200 mg/kg, and decrease in Hb in both sexes at 200 mg/kg and in males at 100 mg/kg, as well as Ht in males at 100 and 200 mg/kg and RBC in females at 200 mg/kg. On blood biochemical examination, increases in total



Fig. 2. Body weight curves in the 18-day study of 1,1,2,2-tetrabromoethane in newborn rats.
Not significantly different from the controls.

Table 5. Summary of the results of the repeated dose studies of 1,1,2,2-tetrabromoethane in newborn rats.

	Dose-finding Study (4 rats/sex/dose)			Main Study (6 rats/sex/dose)		
Dose (mg/kg/day)	12	50	200	3	12	50
Toxic Effects						
–Death (No. of dead animals)	0	0	0*	0	0	0
–Body weight	–	–	10-20%↓	–	–	–
–Blood biochemical parameters	–	–	TB (↑)	–	–	M: TP (↑)
–Relative liver weight	F: ↑	↑	↑	–	–	↑
–Histopathological changes	n.d.	n.d.	n.d.	0	0	0
(No of animals with the findings)						

M: Males, F: Females, ↑: Increase, ↓: Decrease, (↑): Slight increase, –: No change, TB: Total bilirubin, TP: Total protein, n.d.: No available data, *Although there were no deaths in this group, hypoactivity and bradypnea were observed in all animals.

cholesterol in both sexes, and total protein and triglycerides in females were noted at 200 mg/kg. In addition, increase in total cholesterol was found in females given 100 mg/kg. There were also increases in absolute liver weight in males at 100 and 200 mg/kg and in females at 200 mg/kg, relative liver weight in both sexes at 50 mg/kg and more, and kidney weights in females at 100 mg/kg and in both sexes at the highest dose. Because of the clear toxic effects, 200 mg/kg was selected as the top dose for the main study, and 60, 20 and 6 mg/kg were derived by one third division.

In the main study, there were no significant changes in body weight and food consumption. At scheduled sacrifice, hematological examination showed decrease in platelet counts in females of 200 mg/kg group. On blood biochemical examination, changes suggestive of effects on the liver, including increase in total protein, albumin, A/G, total cholesterol, were found in both sexes at the highest dose. There were also increases in total protein and albumin in females of the 20 and 60 mg/kg groups and increases in A/G in females of the 60 mg/kg groups. For organ weights, there were increases in absolute and relative liver weights of both sexes given 60 and 200 mg/kg and slight increase in relative liver weights in males given 20 mg/kg. In addition, relative kidney weights were higher in both sexes and absolute kidney weights in females of the 200 mg/kg group. On histopathological examination (Table 6), slight to mild centrilobular hypertrophy of hepatocytes was observed in both sexes given 20 mg/kg and more. In the thyroid, mild hypertrophy of follicular cells was found at 60 mg/kg and 200 mg/kg, and follicles were apt to be miniaturized and colloid to be decreased. At the end of the recovery period, changes observed in the scheduled-sacrifice group remained significant but with a tendency for recovery (total protein, total cholesterol, liver and thyroid weights, centrilobular hypertrophy of hepatocytes (Table 6)).

The results of the dose-finding and main study in young rats are summarized in Table 7. As slight hypertrophy of hepatocytes was observed at 20 mg/kg in the main study, the NOAEL was concluded to be 6 mg/kg/day. The unequivocally toxic level was considered to

Table 6. Histological findings in the repeated dose study of 1,1,2,2-tetrabromoethane in young rats (main study).

		Scheduled-sacrifice group					Recovery group	
	Grade	0	6	20	60	200	0	200
Males								
No. of animals examined		5	5	5	5	5	5	5
Liver								
– Centrilobular hepatocyte hypertrophy	±	0	0	3	4	0	0	3
	+	0	0	0	0	5	0	0
					*			
					**			
– Focal necrosis	±	2	1	3	1	5	1	0
Thyroid								
– Hypertrophy of follicular cells	±	0	0	0	1	4	0	0
Females								
No. of animals examined		5	5	5	5	5	5	5
Liver								
– Centrilobular hepatocyte hypertrophy	±	0	0	3	5	1	0	2
	+	0	0	0	0	4	0	0
					**			
					**			
– Focal necrosis	±	0	0	0	0	1	0	0
Thyroid								
– Hypertrophy of follicular cells	±	0	0	0	2	5	0	0
						**		

±: Slight, +: Mild, *: Significantly different from the control group ($p<0.05$), **: Significantly different from the control group ($p<0.01$).

be more than 200 mg/kg because of the lack of effects on body weights and parameters indicative of hepatotoxicity, such as GOT and GPT. Hypertrophy in the liver and thyroid, and increases in some biochemical parameters at this dose were not considered to be sufficient for a conclusion of toxicity.

DISCUSSION

As with human neonates, the metabolic ability of the newborn rat is known to be extremely immature, with a low cytochrome P450 content (Rich and Boobis, 1997) and a low capacity for glucuronidation (Gow *et al.*, 2001). Therefore, it could be predicted that chemicals directly exerting adverse effects might show stronger toxicity in the newborn than in young/adult rats. As expected, our previous comparative studies demonstrated that the susceptibility to four chemicals (4-nitrophenol, 2,4-dinitorophenol, 3-aminophenol, 3-methylphenol), which may exert toxicity without metabolic activation, was 2 to 4 times greater in the newborn than in young rats (Koizumi *et al.*, 2001, 2002, 2003).

In the present study, DBP and TBE, which differ from the earlier chemicals in requiring biotransformation differently from previous chemicals, were therefore examined. Although hitherto there has been no information on the repeated dose toxicity of DBP, hepatotoxicity with slight centrilobular fatty degeneration or cytoplasmic vacuolization has been already reported for TBE (Hollingsworth *et al.*, 1963; NTP, 1996). The present study showed no effects of either chemical on early development in the newborn, but they caused hepatotoxicity, regardless of sex, in both newborn and young animals. The ratios for NOAELs and unequivocally toxic levels (young/newborn rats) for both chemicals are given in Table 8, the NOAELs for DBP and TBE being considerably higher in newborn than in young rats, so that the latter are clearly more susceptible. Unequivocally toxic levels could not be simply estimated for both chemicals because the hepatic influence observed was only hypertrophy of hepatocytes, usually without increase of GOT and GPT. Therefore, values were estimated on the basis of simultaneous changes of organ weights, histopathology, biochemical parameters and body weights. Based on our specified criteria, the unequivocally toxic level for DBP was in contrast lower in newborn than in young rats. Unfortunately an unequivocally toxic level of TBE could not be estimated for newborn or young rats. However, the dose of 200 mg/kg in the newborn dose-finding study was considered to be sufficiently toxic because of the 10 - 20% lowering of body weights observed, although no histopathology was conducted. The same dose in the young rat main study caused mild hypertrophy of hepatocytes but no change of body weights, was not considered a sufficient toxic level. These results suggest that the unequivocally toxic level of TBE in the newborn might be lower than that in young rats. The reasons for difference in susceptibility presumably lie with metabolic pathways and specific characteristics of newborn animals.

Three studies have demonstrated that DBP is conjugated with hepatic glutathione before or after oxidative biotransformation, leading to urinary excretion of cysteine or mercapturic acid derivatives and exhalation of CO_2 (James *et al.*, 1981, Jones and Wells, 1981, Onkenhout *et al.*, 1986). Activity of the conjugation

Table 7. Summary of the results of the repeated dose studies of 1,1,2,2-tetrabromoethane in young rats.

	Dose-finding Study (4 rats/sex/dose)					Main Study (5 rats/sex/dose)			
Dose (mg/kg/day)	10	20	50	100	200	6	20	60	200
Toxic Effects									
– Death (No. of dead animals)	0	0	0	0	0	0	0	0	0
– Body weight	–	–	–	–	–	–	–	–	–
– Blood biochemical parameters	–	–	–	F: TP↑	M: Cho↑ F: Cho, TG, TP↑	–	F: TP, Alb ↑	F: TP, A/G, Alb ↑	Many↑
– Relative liver weight	–	–	↑	↑	↑	–	M: (↑)	↑	↑
– Histopathological changes ±	n.d.	n.d.	n.d.	n.d.	n.d.	0	3M, 3F	4M, 5F	1F
(No of animals with the findings*) +	n.d.	n.d.	n.d.	n.d.	n.d.	0	0	0	5M, 4F

±: Slight, +: Mild, M: Males, F: Females, ↑: Increase, ↓: Decrease, (↑): Slight increase, –: No change, Alb: Albumin, Cho: Total cholesterol, TG: Triglycerides, TP: Total protein, Many: Many parameters including Alb, A/G, Cho and TP, n.d.: No available data, * Centrilobular hypertrophy of hepatocytes.

pathway is supported by a rapid drop in hepatic glutathione level after DBP administration (James *et al.*, 1981). Metabolism via conjugation with glutathione has in fact been indicated in common for dihaloalkanes or dihaloalkenes, such as 1,2-dibromopropane (Zoetemelk *et al.*, 1986), 1,2-dichloropropane (Trevisan *et al.*, 1989), 1,1-dichloroethylene (Jones and Hathway, 1978) and 1,3-dichloropropene (Climie *et al.*, 1979). In the case of 1,2-halogenated ethanes, it is considered that the oxidative metabolites might irreversibly bind to protein and that conjugate derivatives, episulphonium ions, might be responsible for the DNA adduct formation (Shih and Hill, 1981; Ozawa and Guengerich, 1983).

With TBE, Kennedy *et al.* (1993) identified various excretory metabolites after a single oral administration to rats, such as 1,2-dibromoethylene and tribromoethylene in exhaled air and dibromoacetic acid, glyoxylic acid, and oxalic acid in urine. They suggested that a number of metabolic intermediates produced by oxidative biotransformation may be involved in the mutagenicity, hepatotoxicity and nephrotoxicity of the compound. At least, dibromoacetic acid has unequivocal cytotoxicity and mutagenicity (Kargalioglu *et al.*, 2002).

Based on the available information, oxidative biotransformation mediated by cytochrome P450 might be a critical step for the initial hepatotoxic effects of both chemicals. The rate of production of active metabolites, including free radical intermediates, would be expected to be significantly less or negligible in newborn animals at least around 50 mg/kg, at which clearly hepatic changes were observed in young rats for both chemicals, because of their lower content of cytochrome P450 (Rich and Boobis, 1997). This metabolic character for both chemicals as well as the lower blood flow to the liver during the newborn period (Gow *et al.*, 2001) would make a major contribution to the much higher NOAEL in the newborn than in young rats. Similar results have already been demonstrated for aflatoxin B1 (Behroozikha *et al.*, 1992), acetaminophen, bromobenzene and carbon tetrachloride (Gergus and Klaassen, 1998). On the other hand, unequivocally toxic levels for both chemicals appeared to be only 3 to 4 times higher than the NOAELs in newborn rats, in contrast to 25 to >33 times higher in their young counterparts (Table 8). One possible explanation for these differences might be a low capacity for protection against deleterious oxidative stress in the newborn when the toxic chemical burden crosses a threshold in the liver. It has been reported that the content of glutathione and glutathione-*S*-transferase activity in rat liver drops in the early days after birth (Tee *et al.*, 1992).

In our series of comparative studies, the results of the repeated dose toxicity study using newborn rats have been compared with those of routine repeated dose toxicity studies. The routine repeated dose studies have value in identifying target sites for toxicity and providing dose-response information that may be useful for human safety assessment, irrespective of life stage, but the developing period, which could be most vulnerablev to chemical toxicity during life, is not directly evaluated by the studies (Dourson *et al.*, 2002). To compensate for this period, reproductive/developmental toxicity studies that exposed the developing animals via placenta or maternal milk have been conducted. However, the direct exposure to chemicals dur-

Table 8. Comparison of NOAELs and unequivocally toxic levels in newborn and young rats.

	Level (mg/kg/day)		Ratio (young/newborn)
1,3-Dibromopropane			
NOAEL (newborn)	50	× 3	0.2
NOAEL (young)	10		
Unequivocally toxic level (newborn)	150	× 25	1.67
Unequivocally toxic level (young)	250		
1,1,2,2,-Tetrabromoethane			
NOAEL (newborn)	50	× 4*	0.12
NOAEL (young)	6		
Unequivocally toxic level (newborn)	200*	× >33*	>1.0*
Unequivocally toxic level (young)	> 200*		

*: Tentative levels or ratios, due to lack of histology alteration in the newborn and no change in body weight in young rats.